Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$9.57 - $30.41
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Latest price
Market Cap | $1.64B |
EV | $1.97B |
Shares Outstanding | 126.10M |
Beta | 1.00 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $45.64 |
P/E 2025E | - |
P/Revenue 2025E | 5.11x |
Revenue | -70.50% |
EPS | -54.30% |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | 341.50% |
EPS | 11.10% |
Operating Cash Flow | 22.80% |
Free Cash Flow | 16.10% |
Gross Margin 2025E | 99.63% |
Net Profit Margin 2025E | -95.71% |
ROE 2025E | -335.07% |
ROCE 2024 | -262.48% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Arrowhead Pharmaceuticals, Inc.
ARWR
Sector
Healthcare
Industry
Biotechnology
CEO
Anzalone, Christopher
Employees
609
Website
arrowheadpharma.comIPO Date
1993-12-16
Headquarters
177 East Colorado Boulevard, Suite 700, Pasadena, California, 91105, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved